Portopulmonary hypertension: An update

Liver Transplantation

Volumn 18, Issue 8, 2012, Pages 881-891

  Safdar, Zeenat ^a   Bartolome, Sonja ^b   Sussman, Norman ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; ILOPROST; MILRINONE; PROSTACYCLIN; SILDENAFIL; TADALAFIL; UNIPROST; VASODILATOR AGENT;

ANXIETY; BACKACHE; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DYSPEPSIA; FLU LIKE SYM; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HEART VENTRICLE FUNCTION; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE PAIN; INJECTION SITE REACTION; JAW PAIN; LIMB PAIN; LIVER FUNCTION; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NOSE CONGESTION; PERIPHERAL EDEMA; PEROPERATIVE CARE; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SORE THROAT; SYNCOPE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

BLOOD PRESSURE; FEMALE; FIBROSIS; GASTROENTEROLOGY; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PULMONARY ARTERY; RISK FACTORS; SCHISTOSOMIASIS MANSONI; VASODILATOR AGENTS;

EID: 84864472483     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23485     Document Type: Review

References (82)

1. Jyothula S, Safdar Z,. Update on pulmonary hypertension complicating chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2009; 4: 351-363.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (suppl): S43-S54.
3. Sussman NL, Kochar R, Fallon MB,. Pulmonary complications in cirrhosis. Curr Opin Organ Transplant 2011; 16: 281-288.
4. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA,. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-450. (Pubitemid 30489117)
5. Ramsay M,. Portopulmonary hypertension and right heart failure in patients with cirrhosis. Curr Opin Anaesthesiol 2010; 23: 145-150.
6. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ,. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445-2453.
7. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB,. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3: 494-500. (Pubitemid 27427898)
8. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD,. Portopulmonary hypertension: a report from the US-based REVEAL registry. Chest 2012; 141: 906-915.
9. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-1922.
10. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al.; for ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.
11. Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178: 637-643.
12. Murray KF, Carithers RL Jr,; for AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432. (Pubitemid 40770295)
13. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH,. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006; 44: 1502-1510. (Pubitemid 44953655)
14. Pham DM, Subramanian R, Parekh S,. Coexisting hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. J Clin Gastroenterol 2010; 44: e136-e140.
15. Aucejo F, Miller C, Vogt D, Eghtesad B, Nakagawa S, Stoller JK,. Pulmonary hypertension after liver transplantation in patients with antecedent hepatopulmonary syndrome: a report of 2 cases and review of the literature. Liver Transpl 2006; 12: 1278-1282. (Pubitemid 44194597)
16. Ioachimescu OC, Mehta AC, Stoller JK,. Hepatopulmonary syndrome following portopulmonary hypertension. Eur Respir J 2007; 29: 1277-1280. (Pubitemid 46895389)
17. Justino H, Sanders K, McLin VA,. Rapid progression from hepatopulmonary syndrome to portopulmonary hypertension in an adolescent female with hypopituitarism. J Pediatr Gastroenterol Nutr 2010; 50: 334-336.
18. Mal H, Burgière O, Durand F, Fartoukh M, Cohen-Solal A, Fournier M,. Pulmonary hypertension following hepatopulmonary syndrome in a patient with cirrhosis. J Hepatol 1999; 31: 360-364. (Pubitemid 29349765)
19. Shah T, Isaac J, Adams D, Kelly D,; for Liver Units. Development of hepatopulmonary syndrome and portopulmonary hypertension in a paediatric liver transplant patient. Pediatr Transplant 2005; 9: 127-131. (Pubitemid 40238978)
20. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, et al.; for Pulmonary Vascular Complications of Liver Disease Study Group. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48: 196-203. (Pubitemid 351975544)
21. Roberts KE, Fallon MB, Krowka MJ, Benza RL, Knowles JA, Badesch DB, et al.; for Pulmonary Vascular Complications of Liver Disease Study Group. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest 2009; 135: 1470-1475.
22. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, et al.; for Pulmonary Vascular Complications of Liver Disease Study Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835-842.
23. Pellicelli AM, Barbaro G, Puoti C, Guarascio P, Lusi EA, Bellis L, et al. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology 2010; 61: 802-806.
24. Robalino BD, Moodie DS,. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492-498.
25. Pilatis ND, Jacobs LE, Rerkpattanapipat P, Kotler MN, Owen A, Manzarbeitia C, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transpl 2000; 6: 85-91. (Pubitemid 30123373)
26. Mandell MS, Groves BM,. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996; 17: 17-33. (Pubitemid 26100791)
27. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevsky HI,. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11: 1107-1111. (Pubitemid 41341761)
28. Krowka MJ,. Portopulmonary hypertension and the issue of survival. Liver Transpl 2005; 11: 1026-1027. (Pubitemid 41341750)
29. Krowka MJ,. Evolving dilemmas and management of portopulmonary hypertension. Semin Liver Dis 2006; 26: 265-272. (Pubitemid 44141934)
30. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007; 7: 1258-1264. (Pubitemid 46643089)
31. Fix OK, Bass NM, De Marco T, Merriman RB,. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007; 13: 875-885. (Pubitemid 46939441)
32. Sussman N, Kaza V, Barshes N, Stribling R, Goss J, O'Mahony C, et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant 2006; 6: 2177-2182. (Pubitemid 44199553)
33. Molmenti EP, Ramsay M, Ramsay K, Lynch K, Tillmann Hein HA, Molmenti H, et al. Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. Transplant Proc 2001; 33: 1332. (Pubitemid 32237867)
34. Clift PF, Townend JN, Bramhall S, Isaac JL,. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan. Transplantation 2004; 77: 1774-1775. (Pubitemid 38780550)
35. Kaspar MD, Ramsay MA, Shuey CB Jr, Levy MF, Klintmalm GG,. Severe pulmonary hypertension and amelioration of hepatopulmonary syndrome after liver transplantation. Liver Transpl Surg 1998; 4: 177-179. (Pubitemid 28117402)
36. Rafanan AL, Maurer J, Mehta AC, Schilz R,. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000; 118: 1497-1500.
37. Safdar Z,. Targeted oral therapies in the treatment of pulmonary arterial hypertension. Clin Drug Investig 2010; 30: 811-826.
38. Safdar Z,. Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. Respir Med 2011; 105: 818-827.
39. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al.; for Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
40. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-491. (Pubitemid 20100285)
41. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE,. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
42. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al.; for Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804. (Pubitemid 34229650)
43. Chin KM, Rubin LJ,. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 1527-1538. (Pubitemid 351508372)
44. Doran A, Harris S, Goetz B,. Advances in prostanoid infusion therapy for pulmonary arterial hypertension. J Infus Nurs 2008; 31: 336-345.
45. GlaxoSmithKline. Flolan (epoprostenol sodium) for injection. Prescribing information. Published March 2011. Accessed May 2012.
46. Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ,. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest 2009; 135: 130-136.
47. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 2001; 164: 314-318. (Pubitemid 34001301)
48. Ricci GL, Melgosa MT, Burgos F, Valera JL, Pizarro S, Roca J, et al. Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension. Liver Transpl 2007; 13: 1506-1514. (Pubitemid 350168190)
49. Sugimachi K, Soejima Y, Morita K, Ueda S, Fukuhara T, Nagata S, et al. Rapid normalization of portopulmonary hypertension after living donor liver transplantation. Transplant Proc 2009; 41: 1976-1978.
50. Shapiro M, Scurlock C, Raikhelkar J, Weiss A, Anyanwu A, Schachter EN,. Use of inhaled epoprostenol in transition to extubation in a patient after implantation of a ventricular assist device. J Cardiothorac Vasc Anesth 2010; 24: 988-989.
51. Melgosa MT, Ricci GL, García-Pagan JC, Blanco I, Escribano P, Abraldes JG, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl 2010; 16: 348-356.
52. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al.; for Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125. (Pubitemid 36724255)
53. Kim EJ, Shin MS, Oh KY, Kim MG, Shin KC, Park YM, et al. Successful management of portopulmonary hypertension with beraprost. Eur J Gastroenterol Hepatol 2010; 22: 1503-1505.
54. Stähler G, von Hunnius P,. Successful treatment of portopulmonary hypertension with bosentan: case report. Eur J Clin Invest 2006; 36 (suppl 3): 62-66. (Pubitemid 44179784)
55. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl 2008; 14: 287-291. (Pubitemid 351425480)
56. Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ,. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 2011; 139: 109-114.
57. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30: 1096-1102. (Pubitemid 351194755)
58. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25: 502-508. (Pubitemid 40331181)
59. Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004; 23: 321-326. (Pubitemid 38202132)
60. Deibert P, Bremer H, Roessle M, Kurz-Schmieg AK, Kreisel W,. PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension. Eur Respir J 2007; 29: 220-221. (Pubitemid 46092023)
61. Cadden IS, Greanya ED, Erb SR, Scudamore CH, Yoshida EM,. The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation. Ann Hepatol 2009; 8: 158-161.
62. Gough MS, White RJ,. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl 2009; 15: 30-36.
63. Hemnes AR, Robbins IM,. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl 2009; 15: 15-19.
64. Aizawa K, Hanaoka T, Kasai H, Kogashi K, Kumazaki S, Koyama J, et al. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res 2006; 29: 123-128.
65. Palmieri EA, Affuso F, Fazio S, Lembo D,. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004; 141: 743-744. (Pubitemid 39434855)
66. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28: 563-567. (Pubitemid 44794671)
67. Young RA, Ward A,. Milrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1988; 36: 158-192.
68. Chen EP, Bittner HB, Davis RD Jr, Van Trigt P III,. Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. Ann Thorac Surg 1997; 63: 814-821. (Pubitemid 27128706)
69. Chen EP, Bittner HB, Davis RD, Van Trigt P,. Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension. J Heart Lung Transplant 1998; 17: 669-678. (Pubitemid 28389737)
70. Fukazawa K, Poliac LC, Pretto EA,. Rapid assessment and safe management of severe pulmonary hypertension with milrinone during orthotopic liver transplantation. Clin Transplant 2010; 24: 515-519.
71. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O,. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126. (Pubitemid 43049842)
72. McLaughlin VV, McGoon MD,. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431. (Pubitemid 44454562)
73. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10: 174-182. (Pubitemid 38240114)
74. Bandara M, Gordon FD, Sarwar A, Knauft ME, Pomfret EA, Freeman RB, Wirth JA,. Successful outcomes following living donor liver transplantation for portopulmonary hypertension. Liver Transpl 2010; 16: 983-989.
75. Swanson KL, Wiesner RH, Krowka MJ,. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005; 41: 1122-1129. (Pubitemid 40593920)
76. OPTN/UNOS Liver and Intestinal Organ Transplantation Committee Report to the Board of Directors. November 16-17, 2009. Orlando, Florida. Summary. Accessed May 2012.
77. Hovnanian A, Hoette S, Fernandes CJ, Jardim C, Souza R,. Schistosomiasis associated pulmonary hypertension. Int J Clin Pract 2010; 64 (suppl S165): 25-28.
78. de Cleva R, Herman P, Pugliese V, Zilberstein B, Saad WA, Rodrigues JJ, Laudanna AA,. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis-prospective study. Hepatogastroenterology 2003; 50: 2028-2030. (Pubitemid 37467987)
79. Graham BB, Bandeira AP, Morrell NW, Butrous G, Tuder RM,. Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest 2010; 137 (suppl): 20S-29S.
80. Souza R, Fernandes CJ, Jardim CV,. Other causes of PAH (schistosomiasis, porto-pulmonary hypertension and hemolysis-associated pulmonary hypertension). Semin Respir Crit Care Med 2009; 30: 448-457.
81. Ferreira Rde C, Domingues AL, Markman Filho B, Veras FH, Batista LJ, Albuquerque Filho ES,. Hepatopulmonary syndrome in patients with Schistosoma mansoni periportal fibrosis. Acta Trop 2009; 111: 119-124.
82. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB,. Pulmonary-hepatic vascular disorders: a task force report. Eur Respir J 2004; 24: 861-880. (Pubitemid 39504442)